Separation anxiety disorder
disease diseaseOn this page
Summary
Separation anxiety disorder (MONDO:0001098) is a disease and 29 clinical trials. Top therapeutic interventions include vilazodone. A subtype of anxiety disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 29
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | separation anxiety disorder |
| Mondo ID | MONDO:0001098 |
| EFO | EFO:1001916 |
| MeSH | D001010 |
| DOID | DOID:10685 |
| ICD-11 | 830200631 |
| NCIT | C35014 |
| SNOMED CT | 11806006 |
| UMLS | C0003477 |
| MedGen | 1999 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of anxiety disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › separation anxiety disorder
Related subtypes (9): neurocirculatory asthenia, generalized anxiety disorder, phobic disorder, acute stress disorder, neurotic disorder, panic disorder, obsessive-compulsive disorder, anxiety, mixed anxiety and depressive disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Fluvoxamine | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 29.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01999920 | PHASE4 | COMPLETED | Vilazodone for Separation Anxiety Disorder |
| NCT01178385 | PHASE2/PHASE3 | COMPLETED | Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders |
| NCT01416805 | PHASE3 | COMPLETED | Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers |
| NCT00569829 | PHASE2 | COMPLETED | Modular Cognitive Behavioral Therapy for the Treatment of Child Anxiety Disorders in Elementary School Settings |
| NCT00586586 | PHASE2 | COMPLETED | Effectiveness Study of CBT for Anxiety in Children |
| NCT00593515 | PHASE2 | COMPLETED | Effects of Parental Behavior on Child Anxiety Regulation |
| NCT00735995 | PHASE2 | COMPLETED | Effectiveness of Cognitive Behavioral Therapy (CBT) for Child Anxiety Disorders in Community Clinics in Norway |
| NCT01491880 | PHASE1/PHASE2 | COMPLETED | Treatment Study for Rural Latino Youth With Anxiety |
| NCT02051192 | PHASE1/PHASE2 | COMPLETED | Brief Behavioral Treatment for Anxiety in Young Children |
| NCT06661460 | Not specified | RECRUITING | Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders |
| NCT06942429 | Not specified | RECRUITING | Stepped Versus Stratified Care for Anxiety Disorders in Youth |
| NCT07024758 | Not specified | RECRUITING | Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD |
| NCT07228143 | Not specified | RECRUITING | Stepped Care Treatment for Anxiety Resilience |
| NCT07329673 | Not specified | RECRUITING | An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms |
| NCT00104195 | Not specified | COMPLETED | A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions |
| NCT00255112 | Not specified | COMPLETED | TAFF-Psychological Treatment of Separation Anxiety Disorder |
| NCT00774150 | Not specified | COMPLETED | Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study |
| NCT00787397 | Not specified | COMPLETED | Sleep, Mood, and Behavior Study |
| NCT01160588 | Not specified | COMPLETED | Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents |
| NCT01563003 | Not specified | COMPLETED | Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism |
| NCT01565629 | Not specified | COMPLETED | Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders |
| NCT01687764 | Not specified | UNKNOWN | Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children |
| NCT01919970 | Not specified | COMPLETED | Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety |
| NCT01979263 | Not specified | TERMINATED | Attention Bias Modification Treatment for Anxious Youth |
| NCT02028247 | Not specified | COMPLETED | Psychotherapy for Anxiety in Children With Autism Spectrum Disorder |
| NCT02189213 | Not specified | TERMINATED | Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep |
| NCT02305537 | Not specified | COMPLETED | Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment |
| NCT02572973 | Not specified | TERMINATED | Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders |
| NCT02810171 | Not specified | COMPLETED | Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VILAZODONE | 4 | 3 |
| CHEMBL1788361 | 0 | 2 |
Related Atlas pages
- Drugs: Vilazodone